Faron Pharmaceuticals Oy's (LON:FARN) Clevegen cancer treatment has shown its safety credentials in its initial clinical trials.
The biopharma firm said that feedback from a dose escalation study had confirmed that Clevegen had “good tolerability” across all dosing levels tested with no dose limiting toxicity observed, adding that lower doses could potentially induce a “stronger immune response” and was now considering tests on lower dose levels of around 0.1-1 milligrams per kilo (mg/kg) rather than higher dosages of 20 mg/kg as previously planned.
WATCH: 'Immune activation from Clevegen has now been demonstrated' Faron Pharma CEO[hhmc]
Faron also said in line with advice from the studys data monitoring committee it would expand its patient cohort for part I of the trial to 30 to determine optimal dosage before moving to part II.
“Good safety was tRead More – Source
